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(UK) -4.8 (Spain)) vs. 3.2 (1.5 (Germany) -6.6 (Spain), VAS score: 3.8 (range: 3.0 (UK) 
-4.8 (Italy)) vs. 3.1 (range: 1.9 (Germany) -3.9 (Italy)). ConClusions: Among RA 
patients receiving adalimumab or etanercept monotherapy, disease severity was 
similar across the EU5, with patients in Spain and France having relatively lower, 
and patients in Italy, Germany, and UK having relatively higher burden and poorer 
treatment response. Factors influencing the observed patterns of geographic vari-
ation warrant further scrutiny to optimize therapeutic interventions and improve 
outcomes.
PMS10
Efficacy Of NOvEl DMarDS iN Early activE rhEuMatOiD arthritiS: aN 
iNDirEct cOMPariSON
Sawyer L.1, Chang S.1, Diamantopoulos A.2, Dejonckheere F.3
1Symmetron Limited, Herts, UK, 2Symmetron Limited, Borehamwood, UK, 3F. Hoffmann-La Roche, 
Basel, Switzerland
objeCtives: We evaluated the effectiveness of traditional disease-modifying 
antirheumatic drugs (tDMARDs) and novel DMARDs, alone and in combination, 
in methotrexate- and biologic-naive adults with moderate to severe early rheu-
matoid arthritis (ERA; < 3-year duration). Methods: Literature review identified 
randomized controlled trials (RCTs) of tDMARDs and novel DMARDs reporting 
efficacy outcomes (American College of Rheumatology [ACR] 20/50/70/90 response 
and Disease Activity Score at 28 joints [DAS28] remission). Data were pooled using 
Bayesian network meta-analysis techniques. For ACR response, data were analyzed 
using a fixed-effects ordered probit model, which makes efficient use of ordered 
categorical data and guarantees coherent prediction of multinomial response prob-
abilities. For DAS28 remission, data were analyzed with a fixed-effects binomial 
logit model. Sensitivity analyses tested the effects of grouping treatments by class 
and broadening/narrowing inclusion criteria. Results: Results from a synthesis 
of 16 RCTs of tDMARDs (methotrexate, sulfasalazine, hydroxychloroquine) and 
novel DMARDs (biologics [abatacept, adalimumab, etanercept, infliximab, goli-
mumab, tocilizumab] and tofacitinib) indicated that biologics+methotrexate, triple 
tDMARDs, and tocilizumab and tofacitinib monotherapy significantly increased 
response across all ACR categories versus methotrexate. ACR response probabilities 
for biologics+methotrexate were not significantly different between agents. ACR 
response probabilities to novel DMARD monotherapy varied, trending toward higher 
values for tofacitinib and tocilizumab than etanercept or adalimumab. In studies 
reporting DAS28 remission, treatment with tofacitinib or biologics±methotrexate, 
except adalimumab alone, improved remission likelihood versus methotrexate. 
Tocilizumab±methotrexate generated the highest probability of remission among 
biologics and was significantly more effective than other biologics±methotrexate 
and tofacitinib. Results across outcomes were robust to alternative grouping of 
interventions and change in inclusion criteria. ConClusions: Based on ACR 
response, the expected efficacy of biologics+methotrexate, tofacitinib and tocili-
zumab monotherapy, and triple tDMARD therapy appeared higher than MTX in 
ERA. Tocilizumab±methotrexate was expected to have the highest probability 
of generating DAS28 remission and was significantly more effective than other 
biologics±methotrexate and tofacitinib.
PMS11
uSiNg hEalth aSSESSMENt QuEStiONNairE – DiSability iNDEx tO 
EStiMatE EQ-5D utility valuES fOr PatiENtS With rhEuMatOiD 
arthritiS iN taiWaN
Tang C.H.1, Hsu J.Y.1, Hsu P.N.2
1Taipei Medical University, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan
objeCtives: This study aims to provide estimates of EQ-5D as a function of Health 
Assessment Questionnaire – Disability Index (HAQ-DI) scores in patients with 
rheumatoid arthritis (RA) in Taiwan. Methods: Face-to-face patient interviews 
on a total of 140 patients aged between 30 and 70 years old were recruited at the 
rheumatology outpatient clinics of four hospitals located in northern, central and 
southern Taiwan during June 2013-May 2014. The severity distribution of patients 
was mild RA (Disease Activity Score [DAS 28] < 3.2) (N= 57), moderate RA (3.2□…
DAS< 5.1) (N= 44), and severe RA (DAS≥ a5.1) (N= 39). Socio-demographic and clinical 
information were collected, and the HAQ-DI and the EQ-5D questionnaires were 
completed. Generalized linear regression models were used to predict EQ-5D util-
ity values as functions of HAQ-DI scores, age, and gender. Results: Patient mean 
age was 50.8 years old (standard deviation [SD], 11.3 years); 81.4% of the patients 
were women and mean disease duration was 9.65 years (SD, 6.84 years). HAQ-DI 
< 0.5, 58%; 0.5□…HAQ-DI< 1.1, 16%; 1.1□…HAQ-DI< 1.6, 9%, 1.6□… HAQ-DI< 2.1, 12%; 
and HAQ-DI≥ a2.1, 4%. HAQ-DI and EQ-5D mean scores were 12.01 (SD, 7.8) and 0.67 
(SD, 0.34), respectively. The models were able to predict actual EQ-5D across the 
range of the HAQ DI. Age and gender were found to be significant determinants in 
estimating the utility functions. ConClusions: Utility values have very often not 
been assessed in the data collection process in a clinical trial. This study showed 
that HAQ-DI scores can be used to derive EQ-5D utility values for patients with RA 
in Taiwan to facilitate conducting a cost-utility analysis.
PMS12
hEal ratE iN 4,190 frESh fracturES trEatED With lOW-iNtENSity 
PulSED ultraSOuND (liPuS)
Zura R.1, Mehta S.2, Della Rocca G.3, Jones J.4, Steen R.G.4
1Duke University Medical Center, Durham, NC, USA, 2Hospital of the University of Pennsylvania, 
Philadelphia, PA, USA, 3University of Missouri, Columbia, MO, USA, 4Bioventus, LLC, Durham, 
NC, USA
objeCtives: Patient age is one of many potential risk factors for fracture nonunion. 
We evaluate impact of age on heal rate (HR) in patients with fresh fracture (≤ 90 
days old). Our hypothesis is that age is not a risk factor for nonunion if fractures 
are treated with LIPUS. Methods: A LIPUS device was approved in 1994 to acceler-
ate fresh fracture healing, though the FDA required a Post-Market Registry. Patient 
data were collected from October 1994 until October 1998 and were reviewed and 
for patients who do not respond to traditional disease modifying anti-rheumatic 
drugs (DMARDs). This study aimed to compare the efficacy of biological agents with 
traditional DMARDs for methotrexate (MTX) treatment failure patients. Methods: 
Four DMARDs (hydroxychloroquine, sulfasalazine, methotrexate, leflunomide) and 
five anti-TNF drugs (adalimumab, etanercept, golimumab, infliximab, certolizumab) 
were selected according to expert consensus. A systematic search of the published 
systematic reviews was performed including MEDLINE, EMBASE and Cochrane 
Library. Among the identified 52 systematic reviews, 3 systematic reviews were 
finally selected and updated to July 2013. Data extraction and methodological qual-
ity assessment using Cochrane Risk of Bias was performed in pairs. Comparative 
efficacy was analyzed using Baysian mixed treatment comparison (MTC). Results: 
A total of 85 trials from 7,938 citations were included. Nineteen trials were grouped 
as MTX failure patients (mean age: 52.9 years, mean of rheumatoid factor posi-
tive rate: 76.6%). Nine studies were included in the analysis of Health Assessment 
Questionnaire (HAQ). The best treatment was certolizumab combined with MTX (MD 
-0.40,95% CrI -0.95 to 0.13). For comparative effects on DAS 28-ESR < 2.6 (remission), 
4 trials were included in analysis. The best treatment was golimumab combined 
with MTX (OR 24.5, 95% CrI 3.51 to 99.52). For comparative effects on ACR 70, the best 
treatment was certolizumab combination with MTX (OR 10.46, 95% CrI 3.66 to 24.41) 
in 11 trials. ConClusions: In the MTX failure patients, certolizumab combination 
with MTX lowered HAQ score than MTX. The result of DAS 28- ESR< 2.6 (remission), 
golimumab combined with MTX was the most effective treatment. Certolizumab 
combined with MTX was best treatment for the ACR 70 response.
PMS8
Quality Of lifE aSSESSMENtS iN KOrEaN PatiENtS With rhEuMatOiD 
arthritiS (ra): aN aNalySiS frOM thE PhaSE iii trial tO EvaluatE 
EQuivalENcE Of thE EtaNErcEPt biOSiMilar hD203 aND ENbrEl®  
iN cOMbiNatiON With MEthOtrExatE (Mtx) iN PatiENtS With ra;  
thE hEra StuDy
Bae S.C.1, Lee S.R.2, Ahn Y.3
1Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Hanwha Chemical 
Biologics, Seoul, South Korea,, 3Hanwha Chemical, Daejeon, South Korea
objeCtives: Quality of Life (QoL) is important for patients with RA and Enbrel® has 
demonstrated QoL benefits in this patient group. HD203 is an etanercept biosimilar, 
which reported pharmacokinetic bioequivalence to the reference product Enbrel® 
in a Phase I trial and, more recently, demonstrated equivalent efficacy and compa-
rable safety in a phase III randomized trial in Korean patients with RA. Assessing 
QoL was a secondary objective of the HERA study, the results of which are reported 
here. Methods: Patients (male or female aged ≥ 20 years) with active RA were 
randomized (1: 1) to 25 mg HD203 or Enbrel®, administered subcutaneously twice 
weekly with MTX for 48 weeks. QoL assessments (Short Form 36, SF-36; Functional 
Assessment of Chronic Illness Therapy-Fatigue, FACIT-F; EuroQol-5 dimension, 
EQ5D) were undertaken at weeks 24 and 48. Results: In total, 294 patients were 
randomized (147 to HD203; 147 to Enbrel®). There was no significant difference 
between groups on QoL assessments at baseline. QoL assessments were similar 
for HD203 and Enbrel® at week 24 and 48 overall. However, SF-36 Role Emotional 
and Bodily Pain subscales showed significant increase in favour of HD203 at week 
24 (p= 0.0252) and week 48 (p= 0.0243) respectively. No significant difference was 
observed between HD203 and Enbrel® for FACIT-F scores at week 24 or 48, except at 
week 48 for the Emotional Well-being domain, which was significantly improved 
with Enbrel® vs. HD203 (p= 0.0360). No significant differences between groups in 
EQ5D scores were observed at any time. ConClusions: Together with previous 
reports of equivalent pharmacokinetics and efficacy, and comparable safety, these 
data support the biosimilarity of HD203 vs. Enbrel®.
PMS9
cOMPariSON Of DiSEaSE StatuS aND OutcOMES Of PatiENtS With 
rhEuMatOiD arthritiS (ra) rEcEiviNg aDaliMuMab Or EtaNErcEPt 
MONOthEraPy iN EurOPE
Narayanan S1, Lu Y.2, Hutchings R.2, Baynton E.2, Hautamaki E.1
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK
objeCtives: To compare the disease status and outcomes of patients with RA 
receiving adalimumab and etanercept monotherapy in Europe. Methods: A 
multi-country, multi-center medical chart-review study of RA patients was con-
ducted among rheumatologists in UK/France/Germany/Italy/Spain to collect de-
identified data on patients who were recently treated with a biologic as part of 
usual care. Physicians were screened for duration of practice (3-30 yrs) and patient 
volume (incl. > 5 RA biologic patients/month) and recruited from a large panel to 
be geographically representative in each country. Eligible patient charts (≥ 3) were 
randomly selected from a sample of prospective patients visiting each center/prac-
tice during the screening period. Physicians abstracted patient diagnosis, treat-
ment patterns/dynamics and patient symptomatology/disease status/outcomes. 
Patients on adalimumab/etanercept monotherapy were analyzed. Results: 428 
eligible RA patient charts were abstracted; 152 on adalimumab (female: 68%, age: 
52.1yrs, average months on adalimumab: 22.8, 90% on first biologic) and 142 on 
etanercept (female: 70%, age: 50.5yrs, average months on etanercept: 24.6, 97% 
on first biologic). Among patients with available data, latest lab measures docu-
mented were (adalimumab vs. etanercept): ESR: 21.0mm/h (range: 16.1 (UK) -24.6 
(Germany)) vs. 23.4mm/h (range: 13.5 (France) -29.8 (Italy)), CRP: 9.9mg/dl (range: 
5.0 (Italy) -17.0 (Germany)) vs. 13.1mg/dl (range: 7.7 (France) -15.6 (Italy)), rheu-
matoid factor-positive: 81% (range: 68% (Germany) -86% (Spain)) vs. 85% (range: 
62% (Germany) -95% (Spain)), and anti-CPP-positive: 69% (range: 47% (Germany) 
-83% (France)) vs. 74% (range: 61% (Spain) -83% (France)). Latest disease severity 
measures documented were (adalimumab vs. etanercept): Swollen Joint Counts: 
2.7 (range: 2.2 (Spain) -3.5 (Germany)) vs. 2.6 (range: 0.7 (Spain) -6.3 (UK)), Tender 
Joint Counts were 3.9 (range: 3.2 (France) -5.1 (Germany)) vs. 3.7 (range: 1.5 (Spain) 
-7.1 (UK)), Health Assessment Questionnaire (HAQ) rating: 1.6 (range: 0.1 (Spain) 
-2.3 (Germany)) vs. 1.4 (0.3 (Spain) -2.5 (Germany), DAS28 score: 3.8 (range: 2.5 
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abatacept, tocilizumab) for the treatment of moderate-to-severe active rheumatoid 
arthritis (RA) in Greece. Methods: A budget impact model was adapted from a third-
party payer perspective (National Organization for Healthcare Services Provision 
[EOPYY]) to evaluate economic aspects of RA treatment over 5 years (2014–2018). 
The model assumed Greek epidemiological data and local reimbursement require-
ments. Two main scenarios, following either a conservative or an increased market 
uptake of CZP in the Greek health care market, were estimated and individually 
compared to the current market trend scenario, which incorporates original biologics 
erosion from biosimilars entry in the coming year. Costs pertaining to drug acquisi-
tion, administration (only for intravenous drugs), and monitoring were included in 
the analysis and corresponded to 2014 costing year. Officially published sources were 
used to derive unit costs. The outcome measures were the annual cost of treatment 
with bDMARD presented as total cost and disaggregated by drug cost, administration 
cost and monitoring cost, as well as the incremental cost savings per year. Results: 
Comparing CZP current versus conservative market uptake scenarios, the total budget 
was slightly increased by € 0.05 million. In contrast, comparing CZP current versus 
increased market uptake scenarios, the total budgetary savings were € 0.23 million. In 
the latter comparison setting, the cost savings were attributed to reduced drug and 
administration costs. More specifically, the greater replacement of an intravenously 
administered bDMARD (infliximab) conduced to the greater reduction of adminis-
tration costs than in the former comparison setting (cost savings: € 0.17 vs. € 0.14 
million). ConClusions: A potential increased use of CZP treatment was shown to 
be associated with cost savings over the next 5 years in Greece.
PMS16
PharMacOEcONOMic EvaluatiON Of biOlOgic thEraPiES iN ruSSiaN 
PatiENtS With rhEuMatOiD arthritiS aND iNtOlEraNcE Or iNaDEQuatE 
rESPONSE tO cONvENtiONal baSic thEraP
Ryazhenov V.V.1, Gorokhova S.G.1, Maximkin S.A.2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Center for strategic 
research in healthcare, Moscow, Russia
objeCtives: About 2.79% of patientswith rheumatoid arthritis (RA) in Russia receive 
TNF-α inhibitors; this value may vary significantly and depends on limitations of 
regional budgets. In this respect, the aim of our study was to conduct a compara-
tive pharmacoeconomic analysis of the most prevalent TNF-α inhibitors in Russian 
patients with rheumatoid arthritis and intolerance or inadequate response to con-
ventional basic therapy. Methods: An pharmacoeconomic model was developed 
based on the data from indirect comparison of anti-TNF-α agents. The model consid-
ers the use of infliximab, etanercept, certulizumab pegol, adalimumab in patients 
with RA who lost response to conventional basic therapy. Cost-effectiveness and 
costs of TNF-α inhibitors for health care budget were estimated. The cost analysis 
included costs of pharmacotherapy. Infliximab and etanercept are included into the 
list of vital and essential medicines and were considered as accepted technologies 
in budget impact analysis: certulizumab pegol and adalimumab were novel tecnolo-
gies in our model. A 24-weeks horizon was adopted. Sensitivity analysis (SA) was 
performed by changing costs of medicines Results: the costs of therapy in certuli-
zumab pegol and etanercept groups were significantly lower than in infliximab and 
adalimumab groups. The cost-effectiveness ratios (CERs) in terms of ACR20 in 24 
weeks were 703 625.00, 587 776.09, and 4 119 260.82 for certulizumab pegol, etaner-
cept and infliximab groups, respectively. The same was observed in case of ACR50 
and ACR70: a strategy of drug use in certulizumab pegol and etanercept groups 
was preferable in comparison with infliximab and adalimumab groups. Budgetary 
costs for health care system were higher in case of infliximab and adalimumab. SA 
confirmed the robustness of the model ConClusions: The study demonstrated 
that certulizumab pegol and etanercept are an economically effective strategy for 
Russian patients with RA and lost response to conventional basic therapy.
PMS17
MaSt (MiNiMal accESS SPiNal tEchNOlOgiES) vErSuS OPEN SurgEry: 
cOSt aNalySiS frOM hOSPital PErSPEctivE
Lukyanov V.1, Melik-Gusseinov D.1, Borgman B.2, Demourenko D.3, Mlyavykh S.4
1Center of Social Economics, Moscow, Russia, 2Medtronic International, Tolochenaz, Switzerland, 
3Medtronic LLC, Moscow, Russia, 4Scientific Research Institute of Traumatology and Orthopedics, 
Nizhniy Novgorod, Russia
objeCtives: The objective of this study was to determine and compare the resource 
consumption associated with open vs. minimal invasive surgery in patients with 
degenerative spinal disorders in the Russian hospital setting. Methods: Conducted 
cost-analysis was based on Moscow hospital setting, where resource utilization 
associated with average one-level spinal operation was determined through inter-
views with KOLs in spinal surgery. Costs were retrieved from public sources and 
hospital data for the following categories 1) hospital stay; 2) blood transfusion 3) 
consumables (suture materials, hemostatic sponges, disposable instruments); 4) 
time in the operating room; 5) spinal implants/instrumentation; and 6) complica-
tions. Results: The results of the calculations have confirmed MAST economic 
advantages over open surgery (OS). MAST was associated with fewer costs, mainly 
due to shorter stay in intensive care unit (1 vs. 2 days) and general ward (9 vs. 15 
days), no need for blood transfusion and less rate of complications. The difference 
in the duration of surgery, which depends mainly on the speed of approach and 
the installation of implantable structures, is approximately 20 minutes in favor of 
MAST. With the cost of one-hour long surgery at about 6,000 rubles (167$), excluding 
the cost of implantable structures, the use of MAST instead of OS translates into 
savings of 2,000 rubles (56$) per each surgical intervention. As for overall budget 
savings, the use of MAST translates into savings of between 14,783 ($410) and 35,000 
($970) rubles per whole hospital visit, depending on what materials and structures 
are used. ConClusions: The economic evaluation confirms economic domination 
of MAST over OS. Despite initial higher investments, MAST appears to be a cost 
saving alternative to OS, in terms of diminution of actual surgery time, reduction of 
blood transfusion costs, and prevention of post-surgery complications and shorter 
overall length of hospital stay.
validated by a registered nurse. We required 4 data elements to report a patient: date 
when fracture occurred; date when treatment began; date when treatment ended; 
and outcome (healed vs. failed, by clinical and radiological criteria). Data were used 
to calculate: days to treatment (DTT); and days on treatment (DOT). All fresh frac-
tures with DTT, DOT, and outcome are reported. Results: 5,765 patients in the reg-
istry had fresh fracture; 73% of patients (N= 4,190) are reported; 13% of patients were 
lost to follow-up; 11% withdrew or were noncompliant; and 3% died or are miss-
ing outcome. Among compliant patients, HR was 96.2%. Logistic estimates of the 
odds ratio for healing are equivalent for patients aged 30 to 79 years. Nevertheless, 
patients who failed treatment were 4.5 years older than patients who healed (p < 
0.0009). DTT was significantly shorter for patients who healed (p < 0.0001). Data 
show that obesity, smoking, diabetes, vascular insufficiency, osteoporosis, cancer, 
rheumatoid arthritis, and chronic use of NSAIDs reduce HR. ConClusions: LIPUS 
mitigates the effect of age on fracture HR. Patients who used LIPUS had a 96% HR, 
whereas the expected HR averages 93%. Time to treatment was significantly shorter 
among patients who healed (p < 0.0001), suggesting it is beneficial to begin treat-
ment early. Comorbid conditions in conjunction with aging can reduce fracture HR.
PMS13
PaiN thEraPy fOr OStEOarthritiS iN gErMaNy: aNalySiS Of SicKNESS 
fuND claiMS Data
Tomeczkowski J.1, Wimmer A.2, Pappert K.2
1Janssen-Cilag GmbH, Neuss, Germany, 2Janssen-Cilag, Neuss, Germany
objeCtives: Using sickness fund claims data, we sought to determine osteoar-
thritis rate, drug compound class, pain therapy prevalence and type of medical 
specialists providing treatment. Methods: A group of company health-sickness 
funds (approx. 2.1 million insured patients in 2010; 2.5 million insured patients in 
2011) was used. Osteoarthritis was identified based on ICD-10 diagnoses (M16.0-9, 
M17.0-5, M17.9, M19.05, M19.25, M19.85, M19.95), then linked to prescriptions using 
the ATC codes: M01A (nonsteroidal anti-inflammatory drugs, NSAIDS), N02B (anal-
gesics and antipyretics), and N02A (opioids). Furthermore, we determined which 
groups of medical specialists prescribed the drugs. Results: Osteoarthritis was 
diagnosed in 7.8% (in 2010) and in 7.1% (in 2011) of patients. In one year, 65.4% of 
patients received a prescription for at least one drug from the analysed ATC codes: 
81.4% of patients received at least one NSAID, 36.4% an analgesic and antipyretic, 
and 27.4% an opioid. For M01A, diclofenac (54%) was most frequently prescribed; 
the proportion of coxibs was 6%. For N02B, 99% of prescriptions were for metami-
zol; 1% for paracetamol. For N02A, most prescriptions were for tramadol (29%) or 
tilidin (28%). General practitioners most frequently prescribed these drugs (42.2% 
[M01A]/46.2% [N02B]/45.9% [N02A]). ConClusions: In Germany in 2010-2011, OA 
prevalence was 7-8%, and associated with analgesic prescriptions for the majority 
of evaluated patients. Diclofenac (NSAIDs, metamizol (analgesics and antipyretics), 
and tramadol or tilidin (opioids) were most frequently prescribed in each group. 
General practitioners were the most frequent painkiller prescribers.
MuScular-SKElEtal DiSOrDErS – cost Studies
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a buDgEt iMPact aNalySiS Of uStEKiNuMab iN thE MaNagEMENt Of 
PSOriatic arthritiS iN grEEcE
Kousoulakou H.1, Natsikas C.2, Geitona M.1
1University of Peloponnese, Corinth, Greece, 2Janssen Pharmaceutical Greece, Pefki, Greece
objeCtives: Ustekinumab was approved for the treatment of psoriatic arthritis (PsA) 
in September 2013. The objective of the study was to estimate the budget impact 
of ustekinumab in the management of PsA in Greece. Methods: A budget impact 
model was developed in Excel 2010 comparing the total PsA treatment costs in the 
current treatment pathway (including golimumab, adalimumab, etanercept and inf-
liximab) with the respective costs of a treatment mix with the inclusion of usteki-
numab. Market share data for the current treatment pathway were based on market 
research. Epidemiology data were taken from the published literature. Due to lack 
of published data on resource use, a 60-field questionnaire was developed in order 
to collect local data relating to the management of PsA in Greece. Two expert panels 
were convened, one with 8 KOL dermatologists and one with 8 KOL rheumatolo-
gists, with the Delphi technique. Unit costs were retrieved from publically available 
sources. The time horizon was five years and the analysis was conducted from the 
Social Insurance Fund perspective. Results: The total number of eligible patients 
(incident and prevalent cases) was estimated to increase from 6,448 in Year 1 to 7,754 
in Year 5. The total cost in the current treatment pathway was estimated to range 
between € 48.4 million in Year 1 and € 20 million in Year 5. The costs in the treatment 
pathway including ustekinumab were € 47.8 and € 18.5 million, in the respective years. 
Therefore, the addition of ustekinumab in the treatment mix can lead to cumulative 
savings for the Social Insurance Funds of € 7.7 million, over the 5-year time horizon. 
This cost reduction is mainly attributed to the less frequent administration of usteki-
numab. ConClusions: Inclusion of ustekinumab in the treatment mix appears to 
be a cost saving treatment option in the management of PsA in Greece.
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buDgEt iMPact aNalySiS Of cErtOlizuMab PEgOl iN thE MaNagEMENt 
Of PatiENtS With MODEratE-tO-SEvErE activE rhEuMatOiD arthritiS 
iN grEEcE
Tzanetakos C.1, Maniadakis N.1, Kourlaba G.2, Tzioufas A.3, Goules A.3, Theodoratou T.4, 
Christou P.4
1National School of Public Health, Athens, Greece, 2Collaborative Center for Clinical Epidemiology 
and Outcomes Research (CLEO), Athens, Greece, 3Athens Medical School, Athens, Greece, 4UCB 
Pharma, Athens, Greece
objeCtives: To investigate the budgetary impact of increasing the patient share of 
certolizumab pegol (CZP) versus the other recommended biologic disease modifying 
anti-rheumatic drugs (bDMARDs; etanercept, adalimumab, golimumab, infliximab, 
